Sibold William John 4

What Happened William John Sibold, President, CEO and a Director of Madrigal Pharmaceuticals (MDGL), had an automatic sale of 1,663 shares on March 6, 2026, at $431.94 per share for proceeds of $718,316. On March 4, 2026 he also received two awards: 14,995 restricted stock units (RSUs) and a 18,743-share derivative award (option/other equity derivative), each granted at $0.00 (no purchase price).

Key Details

• Transactions filed: Form 4 filed March 6, 2026 (reporting period: March 4, 2026).
• Sale: 1,663 shares disposed on 2026-03-06 at $431.94 — total proceeds $718,316. (Footnote F2)
• Grants: 14,995 RSUs (A) and 18,743-share derivative award (A) reported 2026-03-04 at $0.00.
• Shares owned after the transactions: Not specified in the provided filing excerpt.
• Filing timeliness: Report filed March 6 for March 4 transactions — appears timely (within standard Form 4 reporting window).
• Footnotes of note:
  • F1 (RSUs): 14,995 RSUs vest 25% each year on March 4 of 2027–2030, subject to continued service.
  • F2 (sale): The March 6 sale was automatic to cover tax withholding for RSU vesting and was not at the reporting person’s discretion.
  • F3 (derivative): The derivative award vests 25% on March 4, 2027, then 6.25% on the last day of each successive three‑month period thereafter, subject to continued service.

Context

• The March 6 sale was a tax-withholding sale tied to RSU vesting (routine, automatic), which is different from a discretionary open-market sale and typically does not by itself indicate insider sentiment.
• The RSU and derivative awards are grants, not purchases; vesting schedules mean any future economic benefit depends on continued service and vesting dates.